TheDry Eye Syndrome Treatment Marketwas valued atUSD 5.26 billion in 2024and is projected to grow fromUSD 5.57 billion in 2025toUSD 8.77 billion by 2033, registering a CAGR of5.84%during 20252033. This growth is fueled by increasing healthcare infrastructure investments and the expanding geriatric population, both of which significantly contribute to the rising demand for treatments.
Dry eye disease (DED), medically known askeratoconjunctivitis sicca, is one of the most common ocular surface conditions. It leads to discomfort, fatigue, and visual disturbances that impact quality of life. Symptoms such as burning, itching, sore eyes, redness, and photophobia occur when there is insufficient tear production or lubrication. The condition is strongly linked to health issues like diabetes, thyroid disorders, rheumatoid arthritis, Sjogren's syndrome, and lupus, all of which disrupt tear gland function.
Market Growth Drivers
Upgrading Healthcare Infrastructure:Increased healthcare spending and awareness campaigns are boosting adoption of dry eye treatments, alongside rising disposable incomes and demand for effective solutions.
Geriatric Population Growth:With aging populations more prone to eye conditions, demand is set to surge. Prolonged screen exposure, particularly heightened during the COVID-19 lockdowns, has further amplified symptoms among younger groups, creating a long-term impact on market demand.
Market Challenges
Regulatory delays in drug approvals and potential side effects of medications remain barriers to growth. Developing regions also face a shortage of skilled professionals and limited healthcare infrastructure, slowing market expansion.
Market Opportunities
GrowingRD investments, new drug launches, and advanced technologies like nanomicellar delivery systems are opening doors for more effective therapies. Additionally, the sharp rise in eye strain from digital device use continues to push demand for dry eye treatment products.
Regional Insights
North America:Dominates the market with a CAGR of4.7%, driven by drug approvals, high treatment adoption, and better healthcare access. In the U.S., around6.8% of adultsare affected, with prevalence higher among women (8.8%) than men (4.5%).
Asia-Pacific:Expected to grow fastest at a CAGR of7.1%. Rapid improvements in healthcare infrastructure, rising prevalence of DED, and the presence of regional players likeSanten PharmaceuticalsandOtsuka Holdingsare accelerating market growth.
Product Segment Insights
By Product:Cyclosporine holds nearly60% share, growing at5.12% CAGR, with FDA-approved brands like Restasis and Cequa leading adoption.
By Dosage Form:Liquid drops account for35%+ share, with6.1% CAGR, owing to ease of use and high patient compliance.
By Disease Type:Evaporative dry eye dominates with over80% share, linked to screen time, aging, and reduced blinking rates.
By Distribution Channel:Retail pharmacies lead with45%+ share, growing at5.95% CAGR, thanks to accessibility and pharmacist guidance.
Key Players in the Dry Eye Syndrome Treatment Market
AbbVie Inc.
AFT Pharmaceuticals
Alimera Science
Allergan
Alcon
Bausch Lomb
Can-Fite Biopharma
Eyegate Pharma
Novartis
OASIS Medical
Otsuka Holdings
Oyster Point Pharma Inc.
Santen Pharmaceutical Co. Ltd.
Shire/SARcode Bioscience
Sun Pharmaceutical Industries Ltd.
Recent Developments
July 2022:Aldeyra Therapeutics reported positive trial results for reproxalap ophthalmic solution in treating DED.
Feb 2022:NovaBay Pharmaceuticals launched Avenova Lubricating Eye Drops for dry eye relief.
Jan 2022:Sun Pharma introduced Cequa in Canada, the first nanomicellar technology-based drug for improved ocular penetration.
About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us:
Email:sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website:https://straitsresearch.com/
